Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Price Target of $6.67 According to Brokerages

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) has received an average rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.67.

A number of research firms have issued reports on IPHA. Citigroup raised Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating on shares of Innate Pharma in a report on Monday, September 21st. UBS Group reissued a “buy” rating on shares of Innate Pharma in a research report on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Innate Pharma in a research note on Tuesday, September 22nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $9.00 price objective on shares of Innate Pharma in a research report on Thursday, September 17th.

Innate Pharma Stock Performance

NASDAQ:IPHA opened at $1.46 on Friday. The company has a fifty day simple moving average of $1.77 and a two-hundred day simple moving average of $1.72. Innate Pharma has a 52 week low of $1.17 and a 52 week high of $2.71.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company researches treatments designed to activate or enhance the immune system’s ability to recognize and eliminate tumor cells, with an emphasis on natural killer cells and other components of the innate immune system.

Its pipeline includes lacutamab, an antibody directed at KIR3DL2 that is being studied in certain forms of cutaneous T-cell lymphoma. Innate Pharma has also developed monalizumab, an antibody targeting the NKG2A immune checkpoint, through a collaboration with AstraZeneca.